73 related articles for article (PubMed ID: 2389461)
1. Determination of soluble IL-2 receptors in kidney graft recipients--a 6-month follow-up.
Manfro RC; Pohanka E; Tomlanovich SJ; Benet LZ; Salvatierra O; Garovoy MR
Transplant Proc; 1990 Aug; 22(4):1861-2. PubMed ID: 2389461
[No Abstract] [Full Text] [Related]
2. Soluble CD23 and interleukin-2 receptor levels in renal allograft recipients.
Beksaç M; Dalva K; Gönenç F; Dalva I; Gariboğlu S; Batur N; Cetin S
Transplant Proc; 1993 Apr; 25(2):2145-7. PubMed ID: 8470296
[No Abstract] [Full Text] [Related]
3. Plasma soluble interleukin-2 receptor (IL-2RS) level and activation markers in blood in the follow-up of renal allograft patients.
Malcus C; Pouteil-Noble C; Touraine F; Raffaele P; Touraine JL
Transplant Proc; 1990 Aug; 22(4):1865-6. PubMed ID: 2389463
[No Abstract] [Full Text] [Related]
4. Usefulness of serum interleukin 2 receptor levels in renal allograft recipients.
Plaza JJ; Blum G; Ortiz A; Hernando L; Feijoo E; Sanz J; Garcia R; Egido J; Ortiz F
Transplant Proc; 1992 Feb; 24(1):63-4. PubMed ID: 1539346
[No Abstract] [Full Text] [Related]
5. Soluble IL-2R assay and spontaneous blastogenesis in the immunological monitoring of kidney transplant patients.
de Boccardo G; Albano S; Alvarellos T; Massari P; Giraudo C
Transplant Proc; 1994 Oct; 26(5):2854-6. PubMed ID: 7940899
[No Abstract] [Full Text] [Related]
6. Immune monitoring: does the reality fulfill the promise?
Tice DG; Heintz S; Scruggs B; Hubbell C; Szmalc FS
Transplant Proc; 1993 Aug; 25(4):2654. PubMed ID: 8356709
[No Abstract] [Full Text] [Related]
7. Evaluation of serum immunological parameters in acute renal allograft rejection.
Yang J; Li XW; Zheng FL; Bi ZQ
Transplant Proc; 1996 Jun; 28(3):1443-4. PubMed ID: 8658732
[No Abstract] [Full Text] [Related]
8. WOFIE stimulates regulatory T cells: a 2-year follow-up of renal transplant recipients.
Dresske B; Haendschke F; Lenz P; Ungefroren H; Jenisch S; Exner B; El Mokhtari NE; Lu T; Zavazava N; Faendrich F
Transplantation; 2006 Jun; 81(11):1549-57. PubMed ID: 16770244
[TBL] [Abstract][Full Text] [Related]
9. Urine sediment cytology in the management of renal allograft recipients.
Madras PN; Simpson MA; Cornaby AJ; Dempsey RA; Clowes GH; Monaco AP
Transplant Proc; 1989 Feb; 21(1 Pt 2):1842-3. PubMed ID: 2652599
[No Abstract] [Full Text] [Related]
10. Pre-operative interleukin 2 and interleukin 2 receptor levels may predict subsequent renal allograft rejection.
Cornaby AJ; Simpson MA; Madras PN; Dempsey RA; Clowes GH; Monaco AP
Transplant Proc; 1989 Feb; 21(1 Pt 2):1861-2. PubMed ID: 2652604
[No Abstract] [Full Text] [Related]
11. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
[No Abstract] [Full Text] [Related]
12. Relationship between cellular and molecular markers of inflammation in human kidney allograft rejection.
von Willebrand E; Häyry P
Transplant Proc; 1987 Feb; 19(1 Pt 2):1644-5. PubMed ID: 3079030
[No Abstract] [Full Text] [Related]
13. Levels of interleukin-2 (IL-2) and its receptor (IL-2R) as early indicators of graft rejection in TLI-conditioned, transplanted baboons.
Smit JA; Stark JH; Rasool AJ; Gray CM; Myburgh JA
Transplant Proc; 1991 Feb; 23(1 Pt 1):263. PubMed ID: 1990529
[No Abstract] [Full Text] [Related]
14. The assay of soluble IL-2R receptor levels in graft microenvironment can be helpful in differential diagnosis of transplant dysfunction.
Yussim A; Shapira Z; Shohat B; Shmueli D; Zingerman B; Livne E; Klein T
Transplant Proc; 1991 Feb; 23(1 Pt 1):260-2. PubMed ID: 1990528
[No Abstract] [Full Text] [Related]
15. Interleukin-2 receptor levels in end-stage renal disease and transplant patients.
Di Stefano R; Carmellini M; Zucchelli G; Clerico A; Masini S; D'Elia F; Fossati N; Ambrogi F; Mosca F
Transplant Proc; 1990 Aug; 22(4):1863-4. PubMed ID: 2389462
[No Abstract] [Full Text] [Related]
16. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W
Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
[No Abstract] [Full Text] [Related]
17. Lack of predictivity of serum neopterin, soluble interleukin-2 receptor, and serum amyloid A in long-term kidney transplant recipients.
Magalini SC; Nanni G; Tacchino RM; Avolio AW; Castagneto M
Transplant Proc; 1992 Dec; 24(6):2547-8. PubMed ID: 1465861
[No Abstract] [Full Text] [Related]
18. Interleukin-2 receptor as an immunodiagnostic tool to differentiate rejection from nephrotoxicity.
Smith AY; Citterio F; Welsh M; Kerman RH; Kahan BD
Transplant Proc; 1989 Feb; 21(1 Pt 2):1462-4. PubMed ID: 2652467
[No Abstract] [Full Text] [Related]
19. Infection versus rejection in renal transplantation.
Stathakis C; Stavropoulos-Giokas C; Boletis J; Iatrou C; Kastana O; Papanicolaou M; Vlassis T; Papatheophanis J; Chomatas J
Chemioterapia; 1987 Jun; 6(2 Suppl):494-5. PubMed ID: 3334609
[No Abstract] [Full Text] [Related]
20. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
